Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.41 |
| ▸ | HTR2C | P28335 | 8/20 | 0.41 |
| ▸ | HTR2B | P41595 | 8/20 | 0.41 |
| ▸ | DRD3 | P35462 | 9/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.41 |
| ▸ | HRH1 | P35367 | 6/20 | 0.39 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4871755 | 0.89 | HTR2A (0.43) | HTR2AHTR2CHTR2BDRD3KCNH2 | |
| SCHEMBL4872352 | 0.76 | HTR2C (0.46) | HTR2AHTR2CHTR2BDRD3KCNH2 | |
| SCHEMBL4877007 | 0.75 | HTR2B (0.43) | HTR2AHTR2CHTR2BDRD3KCNH2 | |
| SCHEMBL2311109 | 0.73 | DRD3 (0.41) | HTR2AHTR2CHTR2BDRD3KCNH2 | |
| SCHEMBL4880799 | 0.65 | DRD3 (0.48) | HTR2AHTR2CHTR2BDRD3KCNH2 | |
| SCHEMBL4878438 | 0.65 | HTR2A (0.44) | HTR2AHTR2CHTR2BDRD3KCNH2 | |
| SCHEMBL4878390 | 0.62 | DRD3 (0.59) | DRD3KCNH2HRH1DRD2 | |
| SCHEMBL2310821 | 0.61 | DRD2 (0.39) | HTR2AHTR2CHTR2BDRD3KCNH2 | |
| SCHEMBL2310009 | 0.59 | DRD3 (0.42) | HTR2AHTR2CHTR2BDRD3KCNH2 | |
| SCHEMBL24687752 | 0.58 | STAT3 (0.40) | DRD3KCNH2ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1773844-A1 | COMPOUNDS HAVING AFFINITY FOR THE DOPAMINE D3 RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006002928-A1 | COMPOUNDS HAVING AFFINITY FOR THE DOPAMINE D3 RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269195-A1 | Compounds Having Affinity For the Dopamine D3 Receptor and Uses Thereof in Medicine | DRD3, SLC6A3, DRD2 | HTR2A 220/4885HTR2C 246/4885HTR2B 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.